Shifting Medicine Forward

Drawing on a deep understanding of the underlying causes of some of the most challenging diseases, Ichnos Sciences is pursuing truly disease-centric therapies in oncology and autoimmune disease. We strive to develop novel assets and find new answers to some of medicine’s greatest challenges. Because the world is waiting.

Our path toward disease-centric therapies

oncology
Compound Mechanism Preclinical IND-Enabling phase 1 phase 2 phase 3
ISB 1302 HER2 x CD3 BEAT®
bispecific antibody
Metastatic HER2 + Breast Cancer
     
ISB 1342 CD38 x CD3 BEAT®
bispecific antibody
Relapsed/Refractory Multiple Myeloma (MM)
     
ISB 1908 T-cell engager
2H 2020      
ISB 1909 T-cell engager
1H 2021      
ISB 1442 Innate immune engager
2H 2020      
ISC XXXXX HPK1 inhibitor
2H 2020      
oncology
ISB 1302
HER2 x CD3 BEAT®
bispecific antibody
Metastatic HER2 + Breast Cancer
phase-1
ISB 1342
CD38 x CD3 BEAT®
bispecific antibody
Relapsed/Refractory Multiple Myeloma (MM)
phase-1
ISB 1908
T-cell engager
preclinical
2H 2020
ISB 1909
T-cell engager
preclinical
1H 2021
ISB 1442
Innate immune engager
preclinical
2H 2020
ISC XXXXX
HPK1 inhibitor
preclinical
2H 2020
autoimmune disease
Compound Mechanism Preclinical IND-Enabling phase 1 phase 2 phase 3
ISB 830 OX40 antagonist monoclonal antibody
Atopic Dermatitis (AD)
     
ISB 880 Targeted anti-inflammatory therapy
2H 2020      
autoimmune disease
ISB 830
OX40 antagonist monoclonal antibody
Atopic Dermatitis (AD)
phase-2
ISB 880
Targeted anti-inflammatory therapy
preclinical
2H 2020
pain management
Compound Mechanism Preclinical IND-Enabling phase 1 phase 2 phase 3
ISC 17536* TRPA1 antagonist
Diabetic Peripheral Neuropathy (DPN)
     
pain management
ISC 17536*
TRPA1 antagonist
Diabetic Peripheral Neuropathy (DPN)
phase-2

*Ichnos Sciences will complete preclinical and clinical work required to start a randomized Phase 2b study of ISC 17536 and plans to out-license the compound to enable greater focus on oncology and autoimmune disease.

Note: Assets that were previously identified as GBR and GRC are now identified as ISB (for biologics) and ISC (for small molecules), respectively.

View Career Opportunities

United States

Switzerland

The links above are provided for your convenience, and Ichnos is not responsible for content, privacy or security issues associated with your visit to external websites.